TEC
MOLECULAR TARGETtec protein tyrosine kinase
TEC (tec protein tyrosine kinase) is targeted by 30 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting TEC
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | osimertinib | 5.03 | 152 |
| 2 | ibrutinib | 4.86 | 128 |
| 3 | foretinib | 4.34 | 76 |
| 4 | tozasertib | 4.33 | 75 |
| 5 | bosutinib | 4.08 | 58 |
| 6 | canertinib | 3.53 | 33 |
| 7 | tae 684 | 3.43 | 30 |
| 8 | mln 8054 | 3.33 | 27 |
| 9 | acalabrutinib | 3.22 | 24 |
| 10 | rociletinib | 3.18 | 23 |
| 11 | jnj 7706621 | 3.09 | 21 |
| 12 | at 9283 | 3.09 | 21 |
| 13 | lestaurtinib | 3.04 | 20 |
| 14 | spebrutinib | 3.04 | 20 |
| 15 | pf 03758309 | 3.00 | 19 |
| 16 | danusertib | 2.94 | 18 |
| 17 | r 406 | 2.83 | 16 |
| 18 | ritlecitinib | 2.77 | 15 |
| 19 | apitolisib | 2.71 | 14 |
| 20 | zanubrutinib | 2.56 | 12 |
| 21 | mk 5108 | 2.48 | 11 |
| 22 | poziotinib | 2.48 | 11 |
| 23 | evobrutinib | 2.48 | 11 |
| 24 | azd 7762 | 2.30 | 9 |
| 25 | asp 3026 | 2.08 | 7 |
| 26 | tirabrutinib | 1.95 | 6 |
| 27 | pf 03814735 | 1.79 | 5 |
| 28 | tolebrutinib | 1.79 | 5 |
| 29 | Dasatinib | 0.69 | 1 |
| 30 | bdb pf 06651600 us11111242 example 5 us9617258 example 5 | 0.69 | 1 |
About TEC as a Drug Target
TEC (tec protein tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 30 compounds with documented TEC interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
TEC inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.